Chronic Heart Failure With Reduced Ejection Fraction, Worsening Chronic Heart Failure
Conditions
Keywords
HFrEF
Brief summary
This is an observational study in which data already collected from people with chronic HFrEF (heart failure with reduced ejection fraction) who have experienced worsening heart failure are studied. Chronic HFrEF is a long-term condition where the left side of the heart does not pump blood out to the body as well as it should. Blood and fluid may collect in the lungs, blood vessels, and tissues causing shortness of breath or tiredness. Over time, heart failure can lead to other serious medical conditions that may result in hospital stays and even death. The study drug, vericiguat, is already approved for doctors to prescribe to people with worsening of heart failure with chronic HFrEF in India. Vericiguat increases the activity of an enzyme called soluble guanylate cyclase (sGC), which relaxes the blood vessels, allowing more blood to flow through. As a result, the heart is able to pump better. The participants in this study are already receiving treatment with vericiguat as part of their regular care from their doctors. There is currently limited real-world data on the use of vericiguat. Furthermore, discussing whether vericiguat treatment should start early in people with heart failure can help doctors manage these people better. The main purpose of this study is to collect information about how well vericiguat works and how safe it is in Indian people with chronic HFrEF who have experienced worsening heart failure. To do this, researchers will collect the following information: * participants' characteristics, including age, sex, height, weight, and medical history * additional medicines participants have taken with vericiguat * other treatment options participants have taken for the treatment of heart failure * levels of NT-pro BNP\* in participants' blood at least one month before taking vericiguat (\*NT-proBNP is made by heart muscles. People with heart diseases have increased levels of NT-proBNP in their blood. Measuring NT-proBNP levels in the blood can help doctors identify heart disease.) * number of participants from India, divided into four zones-North, South, East, and West * categorization of participants based on how heart failure limits physical activity and classification of heart failure by cause * change in heart function measured by how much blood the left side of the heart can pump out * number of hospitalizations and number of participants who died due to heart-related and non-heart-related events * number of participants who experienced low blood pressure or fainting after starting treatment with vericiguat * participants who discontinued treatment with vericiguat, due to low blood pressure or fainting The data will come from the participants' hospital, medical and electronic healthcare records. Data collected will be from Indian people with chronic HFrEF who started taking vericiguat between September 2022 and August 2023. Researchers will track participants' data and will follow them until Feb 2024. In this study, only available data from routine care are collected. No visits or tests are required as part of this study.
Interventions
Prescibed as per local label
Sponsors
Bayer
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients of ≥18 years age. * Patients who are prescribed as per local label will be included in the study * At least one Vericiguat prescription during the time between 01 Sep 2022 and 31 Aug 2023
Exclusion criteria
* Subjects who have participated in an interventional clinical study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Descriptive measurement of baseline clinical characteristics of patients initiated on Vericiguat | At baseline | Clinical characteristics include demographics, concomitant medication, medical history and surgical history, history of hospitalization, N-Terminal Pro Brain Natriuretic Peptide (NT-Pro BNP) levels |
| Descriptive measurement of baseline treatment patterns of patients initiated on Vericiguat | At baseline | — |
| Description of the use of medications of interest (yes/no) before/after initiation of Vericiguat | Up to 12 months | Includes description of prescribed amount of medications of interest in respective observation periods |
| Descriptive measurement of titration patterns | Up to 12 months | Includes starting dose, up-titration / down-titration (yes/no), time until target dose |
| Descriptive measurement of treatment discontinuation | Up to 12 months | Includes descriptive analysis of number of patients who have discontinued treatment, time points of discontinuation, reasons for discontinuation (Symptomatic hypotension, syncope) |
Secondary
| Measure | Time frame |
|---|---|
| Number of patients with hospitalizations due to heart failure after Vericiguat initiation | Up to 12 months |
| Cardiovascular mortality rate | Up to 12 months |
| Composite of heart failure hospitalization and cardiovascular mortality | Up to 12 months |
| Number of patients with symptomatic hypotension or syncope after Vericiguat initiation | Up to 12 months |
Countries
India
Outcome results
None listed